Experimental drug lowers serum phosphate in phase 3 trial of hemodialysis patients

In a phase 3 clinical trial, tenapanor significantly lowered elevated blood phosphate in patients receiving maintenance hemodialysis, resulting in an average reduction of 1.0-1.2 mg/dL over eight weeks. Side effects were largely limited to softening of stool and more frequent bowel movements.

Leave a Reply

Your email address will not be published. Required fields are marked *